GlassScriptPhysician profile
Razvan T Dadu
NPI 1427201375
$22,708.61
in general payments reported to CMS, 2019-2025
42 companies · $3,609 in 2025
The $3,609 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,894 · 2020: $489 · 2021: $729 · 2022: $2,621 · 2023: $4,140 · 2024: $5,227 · 2025: $3,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,456.70 |
| Travel and Lodging | $2,518.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,318.21 | 2019-2025 | Mitraclip, Aveir, Triclip |
| Edwards Lifesciences Corporation | $5,214.14 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Evoque |
| Boston Scientific Corporation | $2,456.67 | 2019-2025 | Watchman Flx, Comet, Ilab Ultrasound Imaging System |
| Abiomed | $2,044.76 | 2019-2025 | Impella |
| Medtronic, INC. | $1,736.80 | 2022-2025 | Onyx Frontier, Micra, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $777.09 | 2019-2024 | Xarelto |
| Amgen INC. | $769.12 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $721.11 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $297.95 | 2019-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $286.66 | 2020-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.52 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $228.58 | 2019-2025 | |
| Medtronic Vascular, INC. | $215.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $194.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $185.20 | 2019-2025 | Verquvo, Winrevair |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Razvan Dadu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.